Invention Grant
US09359315B2 Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
有权
用于治疗多发性硬化的取代的2,3-二氢-1H-茚-1-酮维生素A相关的孤儿核受体拮抗剂
- Patent Title: Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
- Patent Title (中): 用于治疗多发性硬化的取代的2,3-二氢-1H-茚-1-酮维生素A相关的孤儿核受体拮抗剂
-
Application No.: US14469900Application Date: 2014-08-27
-
Publication No.: US09359315B2Publication Date: 2016-06-07
- Inventor: Hariprasad Vankayalapati , Venkatakrishnareddy Yerramreddy
- Applicant: Arrien Pharmaceuticals LLC
- Applicant Address: US UT Salt Lake City
- Assignee: Arrien Pharmaceuticals LLC
- Current Assignee: Arrien Pharmaceuticals LLC
- Current Assignee Address: US UT Salt Lake City
- Agency: Gibson & Dernier LLP
- Agent Timothy X. Gibson, Esq.
- Main IPC: C07D295/116
- IPC: C07D295/116 ; C07D241/04 ; C07D413/10 ; C07D401/10 ; C07D413/12 ; C07D295/135 ; C07D213/50 ; C07D211/14 ; C07C323/22 ; C07D231/12 ; C07D277/42 ; C07D211/38 ; C07D211/58
Abstract:
The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt)/RORγ. The compounds of the present invention are useful for modulating RORγt)/RORγ activity and for treating diseases or conditions mediated by RORγt)/RORγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.
Public/Granted literature
Information query
